Provided by Tiger Trade Technology Pte. Ltd.

LISATA THERAPEUTICS INC

1.14
-0.0350-2.99%
Volume:562.53K
Turnover:684.05K
Market Cap:12.26M
PE:-0.69
High:1.31
Open:1.22
Low:1.13
Close:1.17
52wk High:5.07
52wk Low:0.9875
Shares:10.80M
Float Shares:8.44M
Volume Ratio:24.60
T/O Rate:6.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6418
EPS(LYR):-1.9100
ROE:-101.66%
ROA:-56.74%
PB:1.49
PE(LYR):-0.59

Loading ...

Lisata Therapeutics granted U.S. patent for certepetide in pancreatic cancer

TIPRANKS
·
Yesterday

Lisata Therapeutics Wins US Method-of-Use Patent for Certepetide in Pancreatic Cancer, Solid Tumors

Reuters
·
Yesterday

Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors

THOMSON REUTERS
·
Yesterday

Lisata Unit Marea Therapeutics Doses First Patient in Phase 2 Acromegaly Trial of Mar002

Reuters
·
Oct 05

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of Mar002, a Potential Best-in-Disease Investigational Therapy for the Treatment of Acromegaly

THOMSON REUTERS
·
Oct 05

Lisata Therapeutics President, COO Joshua Lehrer-Graiwer Files Initial Beneficial Ownership Statement

Reuters
·
Sep 29

Lisata Unit Marea to Present Phase 2b TYDAL Data on Mar001 at AHA Scientific Sessions 2026

Reuters
·
Sep 24

Lisata Therapeutics Acquires Marea Therapeutics in Pipeline Pivot Toward Cardioendocrine Drugs

Reuters
·
Sep 17

Lisata Therapeutics, - Acquisition Structured as Stock-for-Stock Deal with Lisata Common and Series C Preferred Stock

THOMSON REUTERS
·
Sep 17

Lisata Therapeutics, - Post-Deal, Lisata Holders Own 2.39%, Marea Holders 59.54%, Investors 38.07% of Common Stock

THOMSON REUTERS
·
Sep 17

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

THOMSON REUTERS
·
Sep 17

Lisata Therapeutics, - to Use Net Proceeds to Advance Mar001/005 and Mar002 with Topline Phase 2 Data Expected Q4 2027

THOMSON REUTERS
·
Sep 17

Lisata Therapeutics, - Investors to Receive 150,867.995 Series C Preferred Shares at $1,491.37 Per Share

THOMSON REUTERS
·
Sep 17

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Reuters
·
Sep 17

U.S. Stocks on the MOVE-Expeditors International, Waters, Wayfair

Reuters
·
Aug 05

Lisata Therapeutics provides update following termination of Kuva Labs merger

TIPRANKS
·
Aug 04

Lisata Therapeutics Sues Kuva Labs over Breached Merger Agreement, Seeks $2 Million Fee

Reuters
·
Aug 04

Lisata Therapeutics - Eliminates Executive Vice President of R&D and Chief Medical Officer Position

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics - Implements Reduction in Force of About 72% of Full-Time Employees

THOMSON REUTERS
·
Aug 04

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

THOMSON REUTERS
·
Aug 04